Seres Therapeutics, Inc.

NASDAQ:MCRB

Biotechnology

Healthcare
$5.28 +1.70%

+$0.11 today

Market cap
$51.13M
Beta
0.11
P/E (TTM)
-1.3
EPS (TTM)
-$4.89
52W Low $5.31High $29.98

Volume 0.04M

Average 0.06M

MCRB Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Seres Therapeutics, Inc.NASDAQ: MCRB

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $13.2M rose 11.6% year over year, ahead of the -33.6% change in trailing-twelve-month research & development. Sequentially, it rose 12.9% from the prior quarter. Over 3 fiscal years it compounded at -23.5% a year.

Context

  • Research & development amounted to 6218.0% of revenue in FY2025.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +11.6% holds above the trailing-twelve-month pace of -33.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$13.2M+12.9% QoQ
Last fiscal yearDec 2025
$49.06M-24.1% YoY
LTMMar 2026
$37.82M-33.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.6%——
1 year-24.1%——
3-year CAGR-23.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
49.06M USD
Year-over-year change
-24.1%
4-year CAGR
-23.3%

Research & Development vs competitors

How MCRB compares with its peers on the latest reported figures

  • MCRB's LTM Mar 2026 research & development of $37.82M is the 4th highest of the 9 companies compared; the peer median is $32.94M.
  • Its year-over-year change of -33.6% is the 7th highest of 9, against a peer median of -16.9%.
  • Research & development amounts to 3297.1% of revenue for MCRB, versus a peer median of 274.8%.
MCRB Competitors Peer median
Research & Development for MCRB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$96.1M -9.9%+48.0%—
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$51.51M -27.2%-33.9%—
SEERSeer, Inc.LTM Mar 2026$41.33M -11.2%-6.2%274.8%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$37.82M -33.6%-23.5%3297.1%
IRDOpus Genetics, Inc.LTM Mar 2026$33.44M +11.2%+29.0%279.0%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$32.45M -22.6%+7.0%—
SPROSpero Therapeutics, Inc.LTM Mar 2026$27.77M -70.1%-6.9%50.7%
HURATuHURA Biosciences, Inc.LTM Mar 2026$21.18M +82.5%+30.2%—
ACTUActuate Therapeutics IncLTM Mar 2026$9.64M -35.9%-14.4%—
Peer median (excluding MCRB) $32.94M-16.9%+0.4%274.8%

Competitors are the stored peer set for MCRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue144.93M000789K
Cost of Revenue0019.34M3.53M4.13M
Gross Profit144.93M0(19.34M)(3.53M)(3.34M)
Gross Margin100.0%———-423.8%
Research & Development141.89M109.65M117.6M64.6M49.06M
Selling, General & Admin69.26M70.26M77.5M53.18M39.16M
Operating Expenses209.42M179.91M175.76M117.78M90.63M
Depreciation & Amortization5.95M6.63M6.24M5.47M4.13M
EBITDA(56.72M)(170.93M)(181.42M)(120.3M)9.83M
EBITDA Margin-39.1%———1245.8%
Operating Income(64.49M)(179.91M)(195.1M)(121.32M)(93.97M)
Operating Margin-44.5%———-11910.1%
Interest Income2.87M3.06M7.3M3.97M2.23M
Interest Expense2.91M6.02M13.18M00
Other Income / Expenses(1.09M)(3.67M)4.97M(4.46M)99.67M
Income Before Tax(65.58M)(183.58M)(190.13M)(125.77M)5.7M
Pre-Tax Margin-45.2%———721.9%
Income Tax Expense00000
Net Income(65.58M)(250.16M)(113.72M)(146.57M)5.7M
Net Margin-45.2%———721.9%
EPS (Basic)(14.30)(46.29)(17.77)(18.86)0.64
EPS (Diluted)(14.30)(46.29)(17.77)(18.86)0.64
Weighted Avg Shares4.59M5.4M6.4M7.77M8.86M
Weighted Avg Shares (Diluted)4.59M5.4M6.4M7.77M8.87M

Seres Therapeutics, Inc.

NASDAQ:MCRB

Intrinsic Alpha fair value

Locked

Current Price

$5.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.